<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939820</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-TTR02-007</org_study_id>
    <nct_id>NCT02939820</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)</brief_title>
  <official_title>Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide expanded access of patisiran to patients with
      hereditary transthyretin-mediated amyloidosis (hATTR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Choosing to participate in an expanded access program is an important personal decision. Talk
      with your doctor and family members or friends about deciding to join a research study. To
      learn more about this study, please have your doctor contact the study research staff using
      the Contacts provided. For general information, see the links provided in More Information.
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>TTR-mediated Amyloidosis</condition>
  <condition>Amyloidosis, Hereditary</condition>
  <condition>Amyloid Neuropathies, Familial</condition>
  <condition>Familial Amyloid Polyneuropathies</condition>
  <condition>Amyloid Neuropathies</condition>
  <condition>Amyloidosis, Hereditary, Transthyretin-Related</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>patisiran (ALN-TTR02)</intervention_name>
    <description>patisiran (ALN-TTR02) administered by intravenous (IV) infusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female greater than or equal to 18 years of age

          -  Have a diagnosis of hATTR

          -  Meet Karnofsky performance status and Polyneuropathy Disability (PND) score
             requirements

          -  Have adequate complete blood counts, liver function tests and coagulation tests

        Exclusion Criteria:

          -  Participated in an interventional hATTR amyloidosis clinical trial involving RNA
             interference (RNAi) therapeutics within the last 12 months

          -  Are currently eligible to participate in or currently enrolled in an ongoing
             interventional hATTR amyloidosis clinical trial

          -  Have inadequate cardiac function

          -  Known primary amyloidosis (AL amyloidosis) or leptomeningeal amyloidosis

          -  Have known serious comorbidities or considered unfit for the program by the
             investigator

          -  Prior or planned liver or heart transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://ghr.nlm.nih.gov/condition/transthyretin-amyloidosis</url>
    <description>https://ghr.nlm.nih.gov/condition/transthyretin-amyloidosis</description>
  </link>
  <link>
    <url>https://www.nlm.nih.gov/medlineplus/amyloidosis.html</url>
    <description>https://www.nlm.nih.gov/medlineplus/amyloidosis.html</description>
  </link>
  <link>
    <url>https://rarediseases.info.nih.gov/gard/8708/amyloid-neuropathy/resources/1</url>
    <description>https://rarediseases.info.nih.gov/gard/8708/amyloid-neuropathy/resources/1</description>
  </link>
  <link>
    <url>https://rarediseases.info.nih.gov/gard/656/familial-transthyretin-amyloidosis/resources/1</url>
    <description>https://rarediseases.info.nih.gov/gard/656/familial-transthyretin-amyloidosis/resources/1</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RNAi therapeutic</keyword>
  <keyword>FAP</keyword>
  <keyword>Familial Amyloid Polyneuropathies</keyword>
  <keyword>TTR</keyword>
  <keyword>Transthyretin</keyword>
  <keyword>Amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
    <mesh_term>Amyloidosis, Familial</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

